About ViaGen
ViaGen is a Healthcare company based in Austin (United States) founded in 2002, and was acquired by Trans Ova Genetics in June 2012. Cloning services for livestock and pets are offered by Viagen. It operates in the Healthcare and Agriculture sectors. The company was acqui-hired. Its focus areas include Life Sciences, Genomics, Genomics Research and Research Models. Its competitors include Biocytogen, Interius Biotherapeutics and Vytelle; 3 of its 3 listed competitors have raised funding.
Company details
Viagen was founded in 2002 in Austin, United States, as a biotechnology firm focused on animal cloning. Genetic preservation solutions, express tissue banking, and cloning services for livestock and pet animals are provided. Genetically superior animals from herds are utilized in the cloning process. Operations center on advancing reproductive technologies within the agricultural and veterinary sectors.
- Headquarters Austin, United States
- Stage Acquired
- SectorsHealthcareAgriculture
- Website viagen.com
- Social LinkedIn X Facebook
- Acquired by Trans Ova Genetics (Jun 2012)
- Latest Funding Round$149.96K (USD), Grant
Jan 2011
- InvestorsTrans Ova Genetics
& 1 more
- Acquired byTrans Ova Genetics
(Jun 2012)
Funding Insights of ViaGen
- Total Rounds 1
- Last Round Grant — $149,957
- First Round $149,957
(Jan 2011)
- Investors Count 1
All 1 funding rounds of ViaGen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2011 | $149,957 | Grant | – | – |
2 investors in total: 2 institutional.
Investors in ViaGen
ViaGen has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Trans Ova Genetics and National Science Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A government-backed foundation providing seed-stage investments to support small businesses. | 1950 | nsf.gov | Arlington, United States | |
Reproduction and breeding services for livestock genetics are provided. | 1980 | transova.com | Sioux Center, United States |
Investor details for ViaGen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of ViaGen
3 dated milestones of ViaGen across 10 years, from founding to its latest funding, stage changes and deals.
- Founded ViaGen is founded.
- Funding First funding round of $150K.
- Exit Acquired by Trans Ova Genetics.
Competitors of ViaGen
ViaGen has 3 listed competitors in our database, 3 of them funded. They include Biocytogen, Interius Biotherapeutics and Vytelle.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biocytogen.com | 2008 | Wakefield, United States | $301.11M | 85 | Integrated solutions for next-generation antibody drug development are provided. | |
| interiusbio.com | 2020 | Philadelphia, United States | $129.03M | 25 | Developer of gene therapies for treating multiple diseases | |
| vytelle.com | 2015 | Lenexa, United States | $33.2M | 25 | Provider of genetic breeding services for livestock producers |
Detailed competitors of ViaGen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as ViaGen (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about ViaGen
ViaGen was founded in 2002 and raised its 1st funding round 9 years after it was founded.
ViaGen is headquartered in Austin, United States. It is registered at Austin, Texas, United States.
Viagen was founded in 2002 in Austin, United States, as a biotechnology firm focused on animal cloning. Genetic preservation solutions, express tissue banking, and cloning services for livestock and pet animals are provided. Genetically superior animals from herds are utilized in the cloning process. Operations center on advancing reproductive technologies within the agricultural and veterinary sectors.
ViaGen's top competitors include Biocytogen, Vytelle and Interius Biotherapeutics.
ViaGen has 2 investors. Key investors include Trans Ova Genetics, and National Science Foundation.
Yes. ViaGen was acquired by Trans Ova Genetics in June 2012.